{"id":"oxycodone-and-acetaminophen-combination-treatment","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"25-40","effect":"Constipation"},{"rate":"15-25","effect":"Dizziness"},{"rate":"20-30","effect":"Drowsiness"},{"rate":"10-15","effect":"Vomiting"},{"rate":"5-10","effect":"Pruritus"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL656","moleculeType":"Small molecule","molecularWeight":"315.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxycodone is a semi-synthetic opioid agonist that acts on mu, delta, and kappa opioid receptors in the central nervous system to modulate pain signals. Acetaminophen works through inhibition of cyclooxygenase (COX) enzymes and prostaglandin production, providing complementary analgesia. The combination allows for enhanced pain relief at lower individual doses of each component.","oneSentence":"Oxycodone binds to opioid receptors to reduce pain perception, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:22.531Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe acute pain"},{"name":"Post-operative pain management"}]},"trialDetails":[{"nctId":"NCT06757140","phase":"PHASE1, PHASE2","title":"Opioid Drug Interaction Study","status":"RECRUITING","sponsor":"Shanna Babalonis, PhD","startDate":"2025-04-01","conditions":"Drug Interactions, Drug Kinetics","enrollment":25},{"nctId":"NCT03020875","phase":"PHASE4","title":"IV vs Oral Acetaminophen in Spine Fusion Perioperative Care","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital for Special Surgery, New York","startDate":"2017-01","conditions":"Multimodal Analgesic Approach","enrollment":166},{"nctId":"NCT03987022","phase":"PHASE4","title":"ICE-T Pain Regimen for Total Laparoscopic Hysterectomy","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2019-08-01","conditions":"Opioid Substitution Treatment","enrollment":66},{"nctId":"NCT05463367","phase":"PHASE2","title":"Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2021-01-01","conditions":"Opioid Use, Opioid Dependence, Opioid-use Disorder","enrollment":60},{"nctId":"NCT01668849","phase":"PHASE1","title":"Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2012-08-02","conditions":"Head and Neck Cancer, Oral Mucositis","enrollment":60},{"nctId":"NCT01974609","phase":"PHASE4","title":"Narcotic vs. Non-narcotic Pain Study Protocol","status":"COMPLETED","sponsor":"Horizon Health Network","startDate":"2016-03","conditions":"Carpal Tunnel","enrollment":347},{"nctId":"NCT03121963","phase":"PHASE4","title":"Pain Management in Head and Neck Surgery Patients","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2017-11-10","conditions":"Pain Management","enrollment":""},{"nctId":"NCT02480114","phase":"PHASE3","title":"Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2015-07","conditions":"Malignant Head and Neck Neoplasm, Mucositis, Radiation-Induced Disorder","enrollment":79},{"nctId":"NCT02659501","phase":"NA","title":"Liposomal Bupivacaine in Implant Based Breast Reconstruction","status":"TERMINATED","sponsor":"Loma Linda University","startDate":"2015-07","conditions":"Breast Cancer, Postoperative Pain","enrollment":24},{"nctId":"NCT03996564","phase":"NA","title":"Battlefield Acupuncture for Acute/Subacute Back Pain in the Emergency Department","status":"COMPLETED","sponsor":"San Antonio Military Medical Center","startDate":"2016-02-22","conditions":"Low Back Pain, Mechanical","enrollment":26},{"nctId":"NCT01330459","phase":"PHASE4","title":"Hydrocodone For Pain Control in First Trimester Surgical Abortion","status":"COMPLETED","sponsor":"Elizabeth Micks","startDate":"2011-02","conditions":"Pain","enrollment":121},{"nctId":"NCT03137030","phase":"PHASE1","title":"A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults","status":"WITHDRAWN","sponsor":"Grünenthal GmbH","startDate":"2017-09","conditions":"Opioid-Related Disorders, Pain, Acute, Pain, Postoperative","enrollment":""},{"nctId":"NCT03137017","phase":"PHASE1","title":"A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults","status":"WITHDRAWN","sponsor":"Grünenthal GmbH","startDate":"2017-09","conditions":"Opioid-Related Disorders, Pain, Acute, Pain, Postoperative","enrollment":""},{"nctId":"NCT02032927","phase":"PHASE4","title":"Treatment of Chronic Pain From Osteoarthritis","status":"WITHDRAWN","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2013-06","conditions":"Chronic Pain","enrollment":""},{"nctId":"NCT01381120","phase":"PHASE4","title":"Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"Barrie Urology Associates","startDate":"2010-10","conditions":"Flank Pain, Urinary Bladder, Overactive","enrollment":84},{"nctId":"NCT00784810","phase":"PHASE4","title":"A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis","status":"COMPLETED","sponsor":"Napp Pharmaceuticals Limited","startDate":"2009-02","conditions":"Osteoarthritis, Back Pain","enrollment":247}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Oxycodone and acetaminophen combination treatment","genericName":"Oxycodone and acetaminophen combination treatment","companyName":"Barrie Urology Associates","companyId":"barrie-urology-associates","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxycodone and acetaminophen combination treatment is used to manage various types of pain, including low back pain, postoperative pain, and chronic pain, as indicated by ClinicalTrials.gov. The mechanism of action of this combination is not specified in the provided facts, but it is known to be used for pain management, which may involve the analgesic properties of both oxycodone and acetaminophen.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}